RESUMEN
Background: Drug therapy for eye diseases has been limited by multiple protective mechanisms of the eye, which can be improved using well-designed drug delivery systems. Mesoporous silica nanoparticles (MSNs) had been used in many studies as carriers of therapeutic agents for ocular diseases treatment. However, no studies have focused on ocular biosafety. Considering that MSNs containing tetrasulfur bonds have unique advantages and have drawn increasing attention in drug delivery systems, it is necessary to explore the ocular biosafety of tetrasulfur bonds before their widespread application as ophthalmic drug carriers. Methods: In this study, hollow mesoporous silica nanoparticles (HMSNs) with different tetrasulfur bond contents were prepared and characterized. The ocular biosafety of HMSN-E was evaluated in vitro on the three selected ocular cell lines, including corneal epithelial cells, lens epithelial cells and retinal endothelial cells (HREC), and in vivo by using topical eye drops and intravitreal injections. Results: In cellular experiments, HMSNs caused obvious S content-dependent cytotoxic effect. HMSNs with the highest tetrasulfur bond content (HMSN-E), showed the highest cytotoxicity among all the HMSNs, and HREC was the most vulnerable cell to HMSN-E. It was shown that HMSN-E could react with intracellular GSH to generate H2S and decrease intracellular GSH concentration. Treatment of HREC with HMSN-E increased intracellular ROS, decreased mitochondrial membrane potential, and induced cell cycle arrest at the G1/S checkpoint, finally caused apoptosis and necrosis of HREC. Topical eye drops of HMSN-E could cause corneal damage. The intravitreal injection of HMSN-E could induce inflammation in the vitreum and ganglion cell layers, resulting in vitreous opacities and retinal abnormalities. Conclusion: The incorporation of tetrasulfur bonds into HMSN can have toxic effects on ocular tissues. Therefore, when mesoporous silica nanocarriers are designed for ophthalmic pharmaceuticals, the ocular toxicity of the tetrasulfur bonds should be considered.
Asunto(s)
Nanopartículas , Dióxido de Silicio , Humanos , Animales , Nanopartículas/química , Dióxido de Silicio/química , Dióxido de Silicio/toxicidad , Línea Celular , Porosidad , Portadores de Fármacos/química , Apoptosis/efectos de los fármacos , Conejos , Supervivencia Celular/efectos de los fármacos , Ojo/efectos de los fármacos , Soluciones Oftálmicas/química , Soluciones Oftálmicas/farmacología , Compuestos de Organosilicio/química , Compuestos de Organosilicio/toxicidad , Especies Reactivas de Oxígeno/metabolismo , Células Epiteliales/efectos de los fármacos , Células Endoteliales/efectos de los fármacos , Inyecciones IntravítreasRESUMEN
The aim of this study was to develop eye-drops with cefuroxime (CEF) sodium or vancomycin (VAN) hydrochloride, antibiotics that are instable in water. Anhydrous self-emulsifying oils (SEO) are proposed as a carrier and antibiotics are suspended. In the contact with tear fluid, the formulation should transform into emulsion, with fast dissolution of an antibiotic. CEF or VAN (5% w/w) was suspended in SEO carriers prepared by dissolving surfactants (Tween 20 or Span 80 5% w/w) in Miglyol, castor oil, or olive oil. Formulations with or without sodium citrate (2% w/w) were compared. Six-months or 1-year stability tests were carried out at 40 °C. The content of CEF and VAN was evaluated using HPLC and the potency of the antibiotic was assessed with agar diffusion method. In contact with water, drug particles suspended in SEO dissolved rapidly and o/w emulsion was formed. After 1-year at 40 °C, the content of degradation products was at most 0.5% in CEF and 4.0% in VAN formulations. The agar diffusion assay has shown that CEF and VAN loaded into SEO retained its potency against the sensitive microorganisms comparable to an aqueous solution. Therefore, SEO can be used as a novel carrier for the active substances which may not require improved solubility or absorption but need to be protected from moisture. This is a formulation that can be produced on industrial scale, with no limitation of stability or drug concentration.
Asunto(s)
Antibacterianos , Estabilidad de Medicamentos , Emulsiones , Soluciones Oftálmicas , Antibacterianos/administración & dosificación , Antibacterianos/química , Antibacterianos/farmacocinética , Emulsiones/química , Soluciones Oftálmicas/química , Hidrólisis , Aceite de Ricino/química , Cefuroxima/química , Cefuroxima/administración & dosificación , Cefuroxima/farmacocinética , Vancomicina/química , Vancomicina/administración & dosificación , Tensoactivos/química , Química Farmacéutica/métodos , Suspensiones , Agua/química , Solubilidad , Polisorbatos/química , Aceite de Oliva/química , Hexosas/química , Portadores de Fármacos/químicaRESUMEN
Sirolimus (SR) is a macrolide with antifungal and antitumor immunosuppressant properties, classified as a selective inhibitor of mammalian target of rapamycin (mTOR). In this study, an ionic in situ gel of SR (SR-SUS-ISG) was formulated using gellan gum, exhibiting stability regardless of temperature and pH variations, causing minimal irritation. Harnessing the physiological conditions of the eye, SR-SUS-ISG underwent gelation upon contact with ions, increasing drug viscosity and prolonging retention on the ocular surface. Concurrently, SR-SUS-ISG displayed favorable shear dilution properties, reducing viscosity at ambient temperature, enhancing fluidity, and facilitating convenient packaging and transport. Biocompatibility assessments on both human corneal epithelial cells and rabbit eyes demonstrated that SR-SUS-ISG could well be tolerated. Pharmacokinetic investigations in rabbit ocular aqueous humor revealed sustained release, improved corneal penetration, and enhanced bioavailability. Additionally, in a rat corneal alkali burn model, SR-SUS-ISG exhibited inhibitory effects on corneal neovascularization, associated with decreased levels of the inflammatory factors VEGF and MMPs. These findings suggested that SR-SUS-ISG held promise as an effective ocular drug delivery system.
Asunto(s)
Geles , Sirolimus , Animales , Conejos , Sirolimus/farmacología , Sirolimus/farmacocinética , Sirolimus/química , Humanos , Geles/química , Córnea/efectos de los fármacos , Córnea/metabolismo , Ratas , Masculino , Polisacáridos Bacterianos/química , Nanopartículas/química , Administración Oftálmica , Neovascularización de la Córnea/tratamiento farmacológico , Ratas Sprague-Dawley , Viscosidad , Sistemas de Liberación de Medicamentos , Soluciones Oftálmicas/química , Soluciones Oftálmicas/farmacología , Línea Celular , Disponibilidad BiológicaRESUMEN
Tear viscosity is a critical property affecting tear distribution and ocular surface stability. While not widely established as a primary diagnostic marker, deviations from normal viscosity can impact ocular health, potentially contributing to conditions such as dry eye syndrome. Despite their importance, traditional viscometers require sample volumes that are not feasible to use with tear volume. This research introduces a novel Quartz Crystal Microbalance (QCM)-based method for tear viscosity measurement, offering a viscometer prototype that operates with minimal sample volumes. Human tear samples, solutions used in artificial eye drops, and various commercial eye drop brands were evaluated. Results show that the QCM method aligns with established viscosity ranges. The average viscosity of healthy human tears was found to be 1.73 ± 0.61 cP, aligning with the typical range of 1-10 cP. Variability in the viscosities of eye drop can be attributed to differences in their chemical compositions. The QCM method offers benefits such as reduced sample consumption and rapid results, enhancing understanding of tear dynamics for ocular health. Further research with larger sample sizes is needed to establish normative viscosity values in healthy individuals and those with dry eye syndrome, which is crucial for validating the device's clinical efficacy.
Asunto(s)
Tecnicas de Microbalanza del Cristal de Cuarzo , Lágrimas , Viscosidad , Lágrimas/química , Tecnicas de Microbalanza del Cristal de Cuarzo/instrumentación , Tecnicas de Microbalanza del Cristal de Cuarzo/métodos , Humanos , Soluciones Oftálmicas/química , Síndromes de Ojo SecoRESUMEN
The literature reveals gaps in the availability of green analytical methods for assessing products containing gatifloxacin (GFX), a fluoroquinolone. Presently, method development is supported by tools such as the National Environmental Methods Index (NEMI) and Eco-Scale Assessment (ESA), which offer objective insights into the environmental friendliness of analytical procedures. The objective of this work was to develop and validate a green method by the NEMI and ESA to quantify GFX in eye drops using HPLC. The method utilized a C8 column (4.6 × 150 mm, 5 µm), with a mobile phase of purified water containing 2% acetic acid and ethanol (70:30, v/v). The injection volume was 10 µL and the flow rate was 0.7 mL/min in isocratic mode at 25°C, with detection performed at 292 nm. The method demonstrated linearity in the range of 2-20 µg/mL, and precision at intra-day (relative standard deviation [RSD] 1.44%), inter-day (RSD 3.45%), and inter-analyst (RSD 2.04%) levels. It was selective regarding the adjuvants of the final product (eye drops) and under forced degradation conditions. The method was accurate (recovery 101.07%) and robust. The retention time for GFX was approximately 3.5 min. The greenness of the method, as evaluated by the NEMI, showed four green quadrants, and by ESA, it achieved a score of 88.
Asunto(s)
Gatifloxacina , Tecnología Química Verde , Límite de Detección , Soluciones Oftálmicas , Gatifloxacina/análisis , Gatifloxacina/química , Cromatografía Líquida de Alta Presión/métodos , Reproducibilidad de los Resultados , Tecnología Química Verde/métodos , Modelos Lineales , Soluciones Oftálmicas/química , Soluciones Oftálmicas/análisis , Fluoroquinolonas/análisis , Fluoroquinolonas/químicaRESUMEN
Ocular disorders, encompassing both common ailments like dry eye syndrome and more severe situations for instance age-related macular degeneration, present significant challenges to effective treatment due to the intricate architecture and physiological barriers of the eye. Polysaccharides are emerging as potential solutions for drug delivery to the eyes due to their compatibility with living organisms, natural biodegradability, and adhesive properties. In this review, we explore not only the recent advancements in polysaccharide-based technologies and their transformative potential in treating ocular illnesses, offering renewed optimism for both patients and professionals but also anatomy of the eye and the significant obstacles hindering drug transportation, followed by an investigation into various drug administration methods and their ability to overcome ocular-specific challenges. Our focus lies on biological adhesive polymers, including chitosan, hyaluronic acid, cellulose, cyclodextrin, and poloxamer, known for their adhesive characteristics enhancing drug retention on ocular surfaces and increasing bioavailability. A detailed analysis of material designs used in ophthalmic formulations, such as gels, lenses, eye drops, nanofibers, microneedles, microspheres, and nanoparticles, their advantages and limitations, the potential of formulations in improving therapeutic outcomes for various eye conditions. Moreover, we underscore the discovery of novel polysaccharides and their potential uses in ocular drug delivery.
Asunto(s)
Celulosa , Quitosano , Ciclodextrinas , Oftalmopatías , Ácido Hialurónico , Poloxámero , Humanos , Quitosano/química , Quitosano/uso terapéutico , Ácido Hialurónico/química , Ácido Hialurónico/uso terapéutico , Celulosa/química , Celulosa/uso terapéutico , Poloxámero/química , Oftalmopatías/tratamiento farmacológico , Ciclodextrinas/química , Ciclodextrinas/uso terapéutico , Sistemas de Liberación de Medicamentos , Animales , Portadores de Fármacos/química , Soluciones Oftálmicas/química , Soluciones Oftálmicas/uso terapéutico , Administración OftálmicaRESUMEN
OBJECTIVE: To study the physicochemical and microbiological stability over 90â¯days of two preservative-free methylprednisolone sodium succinate (MTPSS) 1 and 10â¯mg/mL eye drops for use in ocular pathologies such as Sjögren's syndrome and dry eye syndrome. METHOD: The two eye drops were prepared from injectable MTPSS (Solu-moderin® and Urbason®), water for injection and normal saline solution. In accordance with ICH (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use) guidelines, they were then stored in triplicate under refrigerated conditions (5±3⯰C), at room temperature (25±2⯰C), and at 40⯰C (±2⯰C). In accordance with the USP (United States Pharmacopeia), physicochemical controls of the active ingredient content were carried out by HPLC-UV (High Performance Liquid Chromatography with Ultraviolet detection), together with controls of pH, osmolality, and visual examination. Microbiological sterility was also tested under refrigerated conditions up to 30â¯days in open containers and up to 90â¯days in closed ones. RESULTS: The eye drops stored at 5⯰C were the most stable; in the 1â¯mg/mL eye drops, degradation of the drug fell below 90% from day 21, and in the 10â¯mg/mL eye drops, from day 42. pH change did not vary by ≥1 unit in formulations stored at 5⯰C, unlike the other formulations. Changes in osmolality did not exceed 5% on day 90 in any storage conditions. Samples of non refrigerate eye drops at 10â¯mg/mL, presented a white precipitate from day 14 and 28, respectively. Non-refrigerated 1â¯mg/mL eye drops presented suspended particles on day 90. There were no color changes. Microbiological analysis showed that sterility was maintained for over 90â¯days in the closed containers, although microbial contamination was detected from day 21 in the open containers. CONCLUSIONS: 1â¯mg/mL MTPSS eye drops show physicochemical and microbiological stability for 21â¯days under refrigeration, compared to 42â¯days for 10â¯mg/mL eye drops stored under the same conditions. However, since they do not include preservatives in their composition, they should not be used for more than 7â¯days after opening.
Asunto(s)
Estabilidad de Medicamentos , Almacenaje de Medicamentos , Metilprednisolona , Soluciones Oftálmicas , Conservadores Farmacéuticos , Soluciones Oftálmicas/química , Metilprednisolona/administración & dosificación , Humanos , Contaminación de MedicamentosRESUMEN
Efficiently removing excess reactive oxygen species (ROS) generated by various factors on the ocular surface is a promising strategy for preventing the development of dry eye disease (DED). The currently available eye drops for DED treatment are palliative, short-lived and frequently administered due to the short precorneal residence time. Here, we developed nanozyme-based eye drops for DED by exploiting borate-mediated dynamic covalent complexation between n-FeZIF-8 nanozymes (n-Z(Fe)) and poly(vinyl alcohol) (PVA) to overcome these problems. The resultant formulation (PBnZ), which has dual-ROS scavenging abilities and prolonged corneal retention can effectively reduce oxidative stress, thereby providing an excellent preventive effect to alleviate DED. In vitro and in vivo experiments revealed that PBnZ could eliminate excess ROS through both its multienzyme-like activity and the ROS-scavenging activity of borate bonds. The positively charged nanozyme-based eye drops displayed a longer precorneal residence time due to physical adhesion and the dynamic borate bonds between phenyboronic acid and PVA or o-diol with mucin. The in vivo results showed that eye drops could effectively alleviate DED. These dual-function PBnZ nanozyme-based eye drops can provide insights into the development of novel treatment strategies for DED and other ROS-mediated inflammatory diseases and a rationale for the application of nanomaterials in clinical settings.
Asunto(s)
Síndromes de Ojo Seco , Soluciones Oftálmicas , Especies Reactivas de Oxígeno , Soluciones Oftálmicas/química , Soluciones Oftálmicas/farmacología , Síndromes de Ojo Seco/tratamiento farmacológico , Animales , Especies Reactivas de Oxígeno/metabolismo , Ratones , Estrés Oxidativo/efectos de los fármacos , Córnea/efectos de los fármacos , Córnea/metabolismo , Alcohol Polivinílico/química , Humanos , Depuradores de Radicales Libres/química , Depuradores de Radicales Libres/farmacología , Boratos/química , Nanopartículas/química , MasculinoRESUMEN
Corneal neovascularization (CNV) is one of the common blinding factors worldwide, leading to reduced vision or even blindness. However, current treatments such as surgical intervention and anti-VEGF agent therapy still have some shortcomings or evoke some adverse effects. Recently, SU6668, an inhibitor targeting angiogenic tyrosine kinases, has demonstrated growth inhibition of neovascularization. But the hydrophobicity and low ocular bioavailability limit its application in cornea. Hereby, we proposed the preparation of SU6668 pure nanoparticles (NanoSU6668; size ~135 nm) using a super-stable pure-nanomedicine formulation technology (SPFT), which possessed uniform particle size and excellent aqueous dispersion at 1 mg/mL. Furthermore, mesenchymal stem cell membrane vesicle (MSCm) was coated on the surface of NanoSU6668, and then conjugated with TAT cell penetrating peptide, preparing multifunctional TAT-MSCm@NanoSU6668 (T-MNS). The T-MNS at a concentration of 200 µg/mL was treated for CNV via eye drops, and accumulated in blood vessels with a high targeting performance, resulting in elimination of blood vessels and recovery of cornea transparency after 4 days of treatment. Meanwhile, drug safety test confirmed that T-MNS did not cause any damage to cornea, retina and other eye tissues. In conclusion, the T-MNS eye drop had the potential to treat CNV effectively and safely in a low dosing frequency, which broke new ground for CNV theranostics.
Asunto(s)
Córnea , Neovascularización de la Córnea , Nanopartículas , Soluciones Oftálmicas , Neovascularización de la Córnea/tratamiento farmacológico , Animales , Nanopartículas/química , Soluciones Oftálmicas/química , Córnea/metabolismo , Córnea/efectos de los fármacos , Ratones , Inhibidores de la Angiogénesis/química , Inhibidores de la Angiogénesis/uso terapéutico , Inhibidores de la Angiogénesis/farmacología , Tamaño de la Partícula , Humanos , Masculino , Ratones Endogámicos C57BL , ConejosRESUMEN
Cataract is a leading cause of blindness globally, and its surgical treatment poses a significant burden on global healthcare. Pharmacologic therapies, including antioxidants and protein aggregation reversal agents, have attracted great attention in the treatment of cataracts in recent years. Due to the anatomical and physiological barriers of the eye, the effectiveness of traditional eye drops for delivering drugs topically to the lens is hindered. The advancements in nanomedicine present novel and promising strategies for addressing challenges in drug delivery to the lens, including the development of nanoparticle formulations that can improve drug penetration into the anterior segment and enable sustained release of medications. This review introduces various cutting-edge drug delivery systems for cataract treatment, highlighting their physicochemical properties and surface engineering for optimal design, thus providing impetus for further innovative research and potential clinical applications of anti-cataract drugs.
Asunto(s)
Catarata , Sistemas de Liberación de Medicamentos , Nanomedicina , Humanos , Catarata/tratamiento farmacológico , Nanomedicina/métodos , Sistemas de Liberación de Medicamentos/métodos , Nanopartículas/química , Animales , Cristalino/efectos de los fármacos , Extracción de Catarata , Sistema de Administración de Fármacos con Nanopartículas/química , Soluciones Oftálmicas/química , Soluciones Oftálmicas/farmacocinética , Soluciones Oftálmicas/administración & dosificaciónRESUMEN
The necessity of animal-free performance tests for novel ophthalmic formulation screening is challenging. For this, we developed and validated a new device to simulate the dynamics and physical-chemical barriers of the eye for in vitro performance tests of topic ophthalmic formulations. The OphthalMimic is a 3D-printed device with an artificial lacrimal flow, a cul-de-sac area, a support base, and a simulated cornea comprised of a polymeric membrane containing poly-vinyl alcohol 10 % (w/v), gelatin 2.5 % (w/v), and different proportions of mucin and poloxamer, i.e., 1:1 (M1), 1:2 (M2), and 2:1 (M3) w/v, respectively. The support base is designed to move between 0° and 50° to replicate the movement of an eyelid. We challenged the model by testing the residence performance of poloxamer®407 16 % and poloxamer®407 16 % + chitosan 1 % (PLX16CS10) gels containing fluconazole. The test was conducted with a simulated tear flow of 1.0 mL.min-1 for 5 min. The OphthalMimic successfully distinguished PLX16 and PLX16C10 formulations based on their fluconazole drainage (M1: 65 ± 14 % and 27 ± 10 %; M2: 58 ± 6 % and 38 ± 9 %; M3: 56 ± 5 % and 38 ± 18 %). In conclusion, the OphthalMimic is a promising tool for comparing the animal-free performance of ophthalmic formulations.
Asunto(s)
Soluciones Oftálmicas , Poloxámero , Poloxámero/química , Soluciones Oftálmicas/química , Administración Oftálmica , Fluconazol/administración & dosificación , Impresión Tridimensional , Córnea/efectos de los fármacos , Córnea/metabolismo , Animales , Quitosano/química , Alternativas a las Pruebas en Animales/métodos , Lágrimas/química , Humanos , Gelatina/químicaRESUMEN
This study aimed to develop, optimize, and evaluate hot-melt-extruded ophthalmic inserts capable of sustained release of diquafosol tetrasodium (DQS) via a design of experiments approach. DQS, a tear stimulant for dry eye management, faces challenges of frequent administration and low bioavailability. The developed insert uses biodegradable polymers in varied proportions to achieve sustained release. Optimized through mixture design, the insert completely dissolved within 24 h and maintained a stable drug content, thickness, and surface pH over three months at room temperature. In vitro corneal permeation studies on excised rabbit corneas demonstrated increased bioavailability, suggesting a reduced dosing frequency compared with conventional eye drops. Therefore, this insert has potential to enhance treatment outcomes by improving patient compliance and providing sustained drug effects.
Asunto(s)
Córnea , Preparaciones de Acción Retardada , Polifosfatos , Nucleótidos de Uracilo , Conejos , Animales , Polifosfatos/química , Nucleótidos de Uracilo/administración & dosificación , Nucleótidos de Uracilo/química , Córnea/metabolismo , Córnea/efectos de los fármacos , Soluciones Oftálmicas/administración & dosificación , Soluciones Oftálmicas/química , Disponibilidad Biológica , Liberación de Fármacos , Administración Oftálmica , Composición de Medicamentos/métodos , Implantes de Medicamentos , Calor , Química Farmacéutica/métodosRESUMEN
Strong precorneal clearance mechanisms including reflex blink, constant tear drainage, and rapid mucus turnover constitute great challenges for eye drops for effective drug delivery to the ocular epithelium. In this study, cyclosporine A (CsA) for the treatment of dry eye disease (DED) was selected as the model drug. Two strategies, PEGylation for mucus penetration and cationization for potent cellular uptake, were combined to construct a novel CsA nanosuspension (NS@lipid-PEG/CKC) by coating nanoscale drug particles with a mixture of lipids, DSPE-PEG2000, and a cationic surfactant, cetalkonium chloride (CKC). NS@lipid-PEG/CKC with the mean size â¼173 nm and positive zeta potential â¼+40 mV showed promoted mucus penetration, good cytocompatibility, more cellular uptake, and prolonged precorneal retention without obvious ocular irritation. More importantly, NS@lipid-PEG/CKC recovered tear production and goblet cell density more efficiently than the commercial cationic nanoemulsion on a dry eye disease rat model. All results indicated that a combination of PEGylation and cationization might provide a promising strategy to coordinate mucus penetration and cellular uptake for enhanced drug delivery to the ocular epithelium for nanomedicine-based eye drops.
Asunto(s)
Ciclosporina , Síndromes de Ojo Seco , Fosfolípidos , Polietilenglicoles , Animales , Ciclosporina/química , Ciclosporina/farmacología , Ciclosporina/farmacocinética , Ciclosporina/administración & dosificación , Polietilenglicoles/química , Ratas , Síndromes de Ojo Seco/tratamiento farmacológico , Síndromes de Ojo Seco/patología , Fosfolípidos/química , Ratas Sprague-Dawley , Nanopartículas/química , Sistemas de Liberación de Medicamentos , Cationes/química , Soluciones Oftálmicas/química , Soluciones Oftálmicas/farmacología , Humanos , Masculino , Córnea/metabolismo , Córnea/efectos de los fármacosRESUMEN
OBJECTIVE: To study the physicochemical and microbiological stability over 90 days of two preservative-free methylprednisolone sodium succinate (MTPSS) 1 mg/ml and 10 mg/ml eye drops for use in ocular pathologies such as Sjögren's syndrome and dry eye syndrome. METHOD: The two eye drops were prepared from injectable MTPSS (Solu-moderin® and Urbason®), water for injection and normal saline solution. In accordance with ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) guidelines, they were then stored in triplicate under refrigerated conditions (5 ±3 °C), at room temperature (25 ± 2 °C), and at 40 °C (±2 °C). In accordance with the USP (United States Pharmacopeia), physicochemical controls of the active ingredient content were carried out by HPLC-UV (High Performance Liquid Chromatography with Ultraviolet detection), together with controls of pH, osmolality, and visual examination. Microbiological sterility was also tested under refrigerated conditions up to 30 days in open containers and up to 90 days in closed ones. RESULTS: The eye drops stored at 5 °C were the most stable; in the 1 mg/ml eye drops, degradation of the drug fell below 90% from day 21, and in the 10 mg/ml eye drops, from day 42. pH change did not vary by ≥1 unit in formulations stored at 5 °C, unlike the other formulations. Changes in osmolality did not exceed 5% on day 90 in any storage conditions. Samples of non refrigerate eye drops at 10 mg/ml, presented a white precipitate from day 14 and 28 respectively. Non-refrigerated 1 mg/ml eye drops presented suspended particles on day 90. There were no color changes. Microbiological analysis showed that sterility was maintained for over 90 days in the closed containers, although microbial contamination was detected from day 21 in the open containers. CONCLUSIONS: 1 mg/ml MTPSS eye drops show physicochemical and microbiological stability for 21 days under refrigeration, compared to 42 days for 10 mg/ml eye drops stored under the same conditions. However, since they do not include preservatives in their composition, they should not be used for more than 7 days after opening.
Asunto(s)
Estabilidad de Medicamentos , Almacenaje de Medicamentos , Metilprednisolona , Soluciones Oftálmicas , Conservadores Farmacéuticos , Soluciones Oftálmicas/química , Metilprednisolona/administración & dosificación , Humanos , Contaminación de MedicamentosRESUMEN
Background: To prepare ocular emulsions containing bipartitioned oil droplets to entrap cyclosporin A (0.05% w/w) and etodolac (0.2% w/w) by using castor, olive and silicon oils. Methods: The physicochemical characterizations of prepared emulsions were performed. The drug's biodistribution profiles and pharmacokinetic parameters from emulsions were checked using the ultraperformance liquid chromatography-tandem mass spectrometry method in the ocular tissues of the healthy rabbit eye model. Results: The emulsions displayed 365.13 ± 7.21 nm size and 26.45 ± 2.09 mV zeta potential. The ferrying of two drugs after releasing from emulsions occurred across corneal/conjunctival tissues to enter the vitreous and sclera following a single drop administration into the rabbit's eyes. Conclusion: The dual drug-loaded emulsions were more likely to produce synergistic anti-inflammatory activity for managing moderate-to-severe dry eye disease.
[Box: see text].
Asunto(s)
Ciclosporina , Emulsiones , Etodolaco , Conejos , Animales , Emulsiones/química , Ciclosporina/farmacocinética , Ciclosporina/administración & dosificación , Ciclosporina/química , Etodolaco/química , Distribución Tisular , Tamaño de la Partícula , Síndromes de Ojo Seco/tratamiento farmacológico , Aceite de Ricino/química , Cationes/química , Aceites de Silicona/química , Aceite de Oliva/química , Córnea/efectos de los fármacos , Córnea/metabolismo , Soluciones Oftálmicas/química , Humanos , Liberación de FármacosRESUMEN
Keratin has the potential to function as the gel matrix in an ophthalmic formulation for the encapsulation of the macrolide antibiotic azithromycin. The quality of this formulation was thoroughly evaluated through various analyses, such as in vitro release assessment, rheological examination, intraocular retention studies in rabbits, assessment of bacteriostatic efficacy, and safety evaluations. It is worth mentioning that the gel demonstrated shear thinning properties and exhibited characteristics of an elastic solid, thereby confirming its structural stability. The gel demonstrated a notable affinity for mucosal surfaces in comparison to traditional azithromycin aqueous solutions. In vitro release testing revealed that drug release transpired via diffusion mechanisms, following a first-order kinetic release pattern. Additionally, the formulated gel exhibited remarkable antibacterial efficacy against Staphylococcus aureus and Pseudomonas aeruginosa in bacteriostatic evaluations. Lastly, safety assessments confirmed that the gel eye drops induced minimal irritation and displayed no apparent cytotoxicity, indicating their good safety and biocompatibility for ocular application. Thus, these findings indicated that the prepared azithromycin gel eye drops complied with the requisite standards for ophthalmic preparations.
Asunto(s)
Conjuntivitis Bacteriana , Sistemas de Liberación de Medicamentos , Animales , Conejos , Azitromicina/farmacología , Queratinas/uso terapéutico , Conjuntivitis Bacteriana/tratamiento farmacológico , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Geles/química , Soluciones Oftálmicas/químicaRESUMEN
The eye is the most accessible site for topical drug delivery. Drug's ocular bioavailability is quite low when administered topically as eye drops. Viscosity enhancers are used to increase ocular bioavailability by extending the precorneal residence time of the drug at the ocular site. Cellulose, polyalcohol and polyacrylic acid are examples of hydrophilic viscosity enhancers. The addition of viscosity modifiers increases the amount of time the drug is in contact with the ocular surface. Several polysaccharides have been studied as excipients and viscosity boosters for ocular formulations, including cellulose derivatives such as chitosan (CS), xyloglucan and arabinogalactan (methylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose (HPMC), and sodium carboxymethylcellulose). Viscosity-increasing substances reduce the surface tension, extend the corneal contact time, slow the drainage, and improve the bioavailability. Chitosan is a viscosity enhancer that was originally thought to open tight junction barrier cells in the epithelium. Chitosan thickens the medication solution and allows it to penetrate deeper. Alginate is an anionic polymer with carboxyl end groups that has the highest mucoadhesive strength and is used to improve penetration. Carboxymethylcellulose (CMC), a polysaccharide with a high molecular weight, is one of the most common viscous polymers used in artificial tears to achieve their longer ocular surface residence period. Hyaluronic acid (HA) is biocompatible and biodegradable in nature, and it is available in ocular sustained-release dose forms. A polymer known as xanthan gum is used to increase viscosity. At 0.2% concentration, carbomer forms a highly viscous gel.
Asunto(s)
Administración Oftálmica , Sistemas de Liberación de Medicamentos , Excipientes , Soluciones Oftálmicas , Viscosidad , Humanos , Soluciones Oftálmicas/administración & dosificación , Soluciones Oftálmicas/química , Excipientes/química , Quitosano/química , Celulosa/química , Celulosa/análogos & derivados , Disponibilidad BiológicaRESUMEN
The purpose of this study was to develop a novel baicalein (BAI) loaded glycymicelle ophthalmic solution with small molecule phytochemical glycyrrhizin as nanocarriers and to explore this solution's potential as an antimicrobial agent against ocular infections. The optimized BAI glycymicelles had a high encapsulation efficiency (98.76⯱â¯1.25â¯%), a small particle size (54.38⯱â¯2.41â¯nm), a uniform size distribution (polydispersity indexâ¯=â¯0.293⯱â¯0.083), and a zeta potential of -28.3⯱â¯1.17â¯mV. The BAI glycymicelle ophthalmic solution exhibited an excellent short-term storage stability. BAI glycymicelles significantly increased the apparent solubility and in vitro release capability of BAI. The BAI glycymicelle ophthalmic solution exhibited no hen's egg-chorioallantoic membrane' irritation and strong in vivo ocular tolerance in rabbits. The BAI glycymicelles noticeably enhanced the in vivo corneal permeation. The BAI glycymicelles also precipitated increased in vitro antioxidant activity and significantly improved in vitro antipathogen activities. Various antimicrobial mechanisms, including the destruction of the bacterial cell wall, damage to the bacterial cell membranes, interruptions to the biofilm structure, and the apoptosis of bacteria, were inflicted on BAI glycymicelles. These findings provided useful knowledge regarding the development of a novel ophthalmic solution and formulation of BAI.
Asunto(s)
Antiinfecciosos , Flavanonas , Animales , Conejos , Flavanonas/farmacología , Córnea/metabolismo , Antiinfecciosos/farmacología , Soluciones Oftálmicas/química , Administración Oftálmica , Tamaño de la PartículaRESUMEN
The incorporation of polymers into drug delivery vehicles has been shown to be a useful approach to prolong the residence time of drugs in the precorneal tear film and to improve penetration into biological membranes. The main objective of this research was to formulate novel viscous eye drops with ketotifen as the active ingredient, containing the polysaccharides: chitosan (MCH), hydroxypropyl guar gum (HPG) and hyaluronic acid (SH) alone and in combination as functional polymers. DSC and FT-IR techniques showed the compatibility between ketotifen and polymers. Physicochemical and rheological analysis at ambient and simulated physiological conditions, as well as the evaluation of mucoadhesive properties showed that vehicles containing combinations of polymers have suitable physicochemical and functional properties with demonstrated synergism between combined polymers (MCH and HPG i.e. SH and HPG). The drug permeability was successfully estimated in vitro using HCE-T cell-based models. MTT cytotoxicity assay demonstrates that the tested formulations were non-toxic and well tolerated. In vivo preclinical study on mice revealed that both vehicles containing mixed polymers enhanced and prolonged the antipruritic/analgesic-like effect of ophthalmic ketotifen. Based on these results, both combinations of polysaccharide polymers, especially SH-HPG, could be considered as potential new carriers for ketotifen for ophthalmic use.
Asunto(s)
Cetotifen , Polímeros , Animales , Ratones , Cetotifen/efectos adversos , Soluciones Oftálmicas/química , Espectroscopía Infrarroja por Transformada de Fourier , Polisacáridos/química , Antagonistas de los Receptores HistamínicosRESUMEN
Benzalkonium chloride (BAC) is a useful preservative for ophthalmic solutions but has some disadvantageous effects on corneal epithelium, especially keratinocytes. Therefore, patients requiring the chronic administration of ophthalmic solutions may suffer from damage due to BAC, and ophthalmic solutions with a new preservative instead of BAC are desired. To resolve the above situation, we focused on 1,3-didecyl-2-methyl imidazolium chloride (DiMI). As a preservative for ophthalmic solutions, we evaluated the physical and chemical properties (absorption to a sterile filter, solubility, heat stress stability, and light/UV stress stability), and also the anti-microbial activity. The results indicated that DiMI was soluble enough to prepare ophthalmic solutions, and was stable under severe heat and light/UV conditions. In addition, the anti-microbial effect of DiMI as a preservative was considered to be stronger than BAC. Moreover, our in vitro toxicity tests suggested that DiMI is safer to humans than BAC. Considering the test results, DiMI may be an excellent candidate for a new preservative to replace BAC. If we can overcome manufacturing process issues (soluble time and flushing volume) and the insufficiency of toxicological information, DiMI may be widely adopted as a safe preservative, and immediately contribute to the increased well-being of all patients.